BASEL, Switzerland (Reuters) – Novartis Chief Executive Joe Jimenez is taking a hard look at the drugmaker’s smaller businesses as he reshapes the company for what he expects to be a “brutal” new era in healthcare spending.
At least one of the three sub-scale units – animal health, vaccines and over-the-counter medicines – is not expected to make the cut, he told Reuters in the clearest indication yet of how the review is progressing.
LONDON/ZURICH, March 13 (Reuters) – Biotech fever is
spreading to Europe from the United States with a successful
stock market debut for a cat allergy company in Britain seen as
a bellwether that could help unlock listings in other countries
including Switzerland and France.
Top candidates for a share sale include Swiss firms AC
Immune and Molecular Partners, which are both weighing up a
possible initial public offering (IPO), according to people
familiar with the companies.
ZURICH, March 12 (Reuters) – Privately-held Swiss biotech
company Novimmune, has appointed former Actelion
CFO Andrew Oakley as its new finance chief, increasing
expectations that the company will go public.
Oakley, a UK and Australian citizen who was chief financial
officer of Actelion for a decade, stepped down from the company
last August. He will take up his new role with immediate effect,
ZURICH, March 12 (Reuters) – A nascent economic recovery in
Europe helped Adecco, the world’s largest staffing
agency by sales, beat fourth-quarter profit forecasts and
increase revenue for the first time in seven quarters.
Staffing companies benefit from moderate economic growth as
firms tend to hire temporary workers at the start of a recovery
when they are reluctant to commit to full-time hiring.
BASEL (Reuters) – Outgoing Lufthansa (LHAG.DE: Quote, Profile, Research) boss Christoph Franz vowed to keep Roche (ROG.VX: Quote, Profile, Research) on its current course after shareholders overwhelmingly elected him as chairman of the Swiss drugmaker.
The 53-year-old is taking over as non-executive chairman of the world’s largest drugmaker by market capitalisation from Franz Humer who is stepping down after 16 years as CEO and chairman.
BASEL (Reuters) – Outgoing Lufthansa (LHAG.DE: Quote, Profile, Research, Stock Buzz) boss Christoph Franz vowed to keep Roche (ROG.VX: Quote, Profile, Research, Stock Buzz) on its current course after shareholders overwhelmingly elected him as chairman of the Swiss drugmaker.
The 53-year-old is taking over as non-executive chairman of the world’s largest drugmaker by market capitalization from Franz Humer who is stepping down after 16 years as CEO and chairman.
ZURICH, March 3 (Reuters) – When outgoing Lufthansa
chief executive Christoph Franz takes over as chairman
of Swiss drugmaker Roche on Tuesday, it could be the
start of a new era of less-frosty relations with arch-rival
The departure last year of Novartis architect and
CEO-turned-chairman Daniel Vasella marked the first step towards
a thawing-out process. He had upset Roche, the world’s biggest
cancer drug maker, by building up a 6.2 percent stake in the
group between 2001 and 2003, with the aim of merging the two
firms into one Swiss pharma giant.
ZURICH, Feb 25 (Reuters) – The world’s largest maker of
dental implants, Straumann Holding Ltd, expects to grab
back market share from low-cost competitors by launching its
cheaper products in more markets this year.
Premium implant makers Straumann and local Swiss rival Nobel
Biocare have faced sluggish demand in Europe, their
main market, as cash-strapped consumers cut back on pricey
dental treatment or trade down to cheaper brands.
ZURICH (Reuters) – Switzerland’s defense minister said it was “unthinkable” that his country’s accords with the European Union would be terminated as result of a referendum to curb immigration, saying threats of retaliation by the bloc were overblown.
Swiss voters this month narrowly backed a proposal to curtail immigration, a move that could violate a free movement of citizens pact with the 28-member bloc that came into force in 2002.
ZURICH (Reuters) – Nestled between the peaks of the Swiss Alps, the Hotel Schweizerhof has provided rooms for weary skiers and hikers for more than a century, profiting like scores of other businesses from Switzerland’s close ties to Europe.
But a shock vote last week to cap all immigration to the landlocked country and introduce quotas for those from the European Union, now threatens to cut the hotel off from the pool of workers on which it relies.